



Resinco Capital Partners Announces Sale of Subsidiary

March 31, 2020 - Vancouver, BC – Resinco Capital Partners Inc. (CSE:RIN) (the “**Company**” or “**Resinco**”) announces the execution of a share purchase agreement (the “**Agreement**”) for the sale of all of the issued and outstanding common shares of its wholly-owned subsidiary, ReFormation Pharmaceuticals Corp. (the “**ReFormation Shares**”), to an arm-length purchaser, 360 Life Sciences Corp. (the “**Purchaser**”) of Delaware, United States.

Under the terms of the Agreement, the Purchaser will acquire the ReFormation Shares in exchange for 800,000 common shares in the capital of the Purchaser.

The Agreement contains standard representations, warranties, indemnities and covenants for transactions of this nature. No finder’s fees were paid in connection with the Agreement.

RESINCO CAPITAL PARTNERS INC.:

Company Contact

Mr. Alexander Somjen, CEO
647-362-8998

About Resinco Capital Partners

Resinco Capital Partners is a global investment company which specializes in providing early stage financing to private and public companies as well as medical cannabis pharmaceutical companies. The Company engages in new, early stage investment opportunities in previously underdeveloped assets and obtaining significant positions in early stage investment opportunities that adequately reflect the risk profile.

Website www.resincocp.com

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com